Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status.

  title={Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status.},
  author={Christian Haslinger and Norbert Schweifer and Stephan Stilgenbauer and Hartmut D{\"o}hner and Peter Lichter and Norbert Kraut and Christian Stratowa and Roger Abseher},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={22 19},
  • C. Haslinger, N. Schweifer, R. Abseher
  • Published 1 October 2004
  • Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Genomic aberrations and mutational status of the immunoglobulin variable heavy chain (VH) gene have been shown to be among the most important predictors for outcome in patients with B-cell chronic lymphocytic leukemia (B-CLL). In this study, we report on differential gene expression patterns that are characteristic for genetically defined B-CLL subtypes. MATERIALS AND METHODS One hundred genetically well-characterized B-CLL samples, together with 11 healthy control samples, were… 

Figures and Tables from this paper

Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups

Functional profiling methods allowed us to distinguish KEGG and gene ontology terms showing coordinated gene expression changes across subgroups of CLL, and validated a set of differentially expressed genes according to IgVH status, scoring them as putative prognostic markers in CLL.

Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling.

This study demonstrates the presence of a recurrent gain in 20q13.12 associated with overexpression of the genes located in this region, in CLL cytogenetic subgroups, suggesting that the changes in gene expression are related to alterations in copy number.

Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia

It is confirmed that the prognostic impact of chromosome abnormalities identified by FISH in CLL, particularly the 11q23 deletion and trisomy 12, was associated with a unique gene expression pattern involving cell signalling and apoptosis genes.

Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk

Differences in expression levels of apoptosis- and proliferation-controlling proteins define distinct prognostic subgroups of chronic lymphocytic leukemia and uncover a correlation of levels of CDK4, P27 and P53 proteins with higher hierarchical risk.

Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.

It is demonstrated that genomic abnormalities influence gene expression in CLL by a dosage effect where the expression of genes at the genetic loci of the sites of the somatic genomic abnormality was altered in a fashion according to the type of genomic change.

Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia.

Data suggest that CLLU1 is the first disease-specific gene identified in CLL, which encodes 6 mRNAs with no sequence homology to any known gene, and most transcripts appear to be noncoding.

High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.

It is suggested that IGHV status can be precisely assessed using the expression analysis of LAG3, LPL, and ZAP70 genes, which contribute to the elucidation of CLL pathogenesis and provide novel prognostic markers for possible application in routine diagnostics.

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

Investigation of the role of ATM gene alterations, their biological consequences and their value in predicting disease progression led to a hypothesis that functional abnormalities are responsible for the unfavorable clinical course of patients carrying these point mutations.

The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia.

It is demonstrated that LPL expression is a predictor for survival in CLL, and for this purpose is as good as IGVH mutational status and more reliable than ZAP70 expression when tested in unpurified CLL samples.

Microarray based comparative genome-wide expression profiling of major subtypes of leukemia

Gene expression profiles of four subtypes of leukemia were compared to each other to ascertain the overall association and significance of genes for occurrence of different types of leukemia which would guide in the development of common probable biomarkers for leukemias followed by effective diagnosis, prognosis and treatment.



Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells 〉

Comparison of CLL profiles with those of purified normal B cell subpopulations indicates that the common CLL profile is more related to memory B cells than to those derived from naive B cells, CD5+ B Cells, and GC centroblasts and centrocytes.

Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

Using genomic-scale gene expression profiling, CLL is characterized by a common gene expression “signature,” irrespective of Ig mutational status, suggesting that CLL cases share a common mechanism of transformation and/or cell of origin.

Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations.

A comprehensive DNA microarray dedicated to the automated analysis of recurrent genomic imbalances in B-CLL by array-based comparative genomic hybridization (matrix-CGH) revealed a high specificity and sensitivity that fulfils the criteria for application in clinical oncology.

Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course

Genetic aberrations and VH mutation status appear to give prognostic information irrespective of the clinical stage and may therefore allow a risk assessment for individual patients early in the course of their disease.

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

In multivariate analysis, p53 gene deletion was the strongest prognostic factor for survival and predicts for non-response to therapy with purine analogs and for poor survival in chronic B-cell leukemias.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Ig V gene mutation status and the percentages of CD38(+) B-CLL cells appear to be accurate predictors of clinical outcome in B- CLL patients, and future evaluations of new therapeutic strategies and drugs should take into account the different natural histories of patients categorized in these manners.

Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.

Interestingly, the subset of mutated cases using the V(H)3-21 gene displayed distinctive genotypic/phenotypic characteristics with shorter average length of the complementarity determining region 3 and clonal expression of lambda light chains, and showed significantly shorter survival than other mutated cases.

B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions.

The alignment of the gene with all critical subregions provides a strong argument for BCMS being the most likely candidate for the tumor suppressor gene in 13q14 involved in the leukemogenesis of B-CLL.

Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

This study evaluates the prognostic significance of genetic abnormalities, clinical stage, lymphocyte morphology, CD38 expression, and IGVH gene status in 205 patients with chronic lymphocytic leukemia.

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Despite having several characteristics of naïve B cells, chronic lymphocytic leukemia (CLL) cells have been shown in some cases to have somatically mutated Ig variable region genes, indicating that